Clinical Trial Update: Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension) [Phase 3]

View source ↗

Summary

A Phase 3 extension study evaluating safinamide as add-on therapy for early Parkinson's disease in patients on a single dopamine agonist. The study reports resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED